Chengdu Push Bio-technology Competitors and Similar CompaniesClear all

Chengdu Push Bio-technology's competitors and similar companies include Pfizer, Fortrea and Novartis.

	Chengdu Push Bio-technology Chengdu Push Bio-technology (成都普思生物科技股份有限公司) is a provider of separation and purification of natural medicines and pharmaceutical research services.	Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.	Fortrea Fortrea Holdings (formerly known as Labcorp Clinical Development and Commercialization Services) is a contract research organization (CRO).	Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products.
Founding Date	Founding Date 2005	Founding Date 1849	Founding Date 2023	Founding Date 1996
Type	Type Private	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development oncology pharma
Locations	Locations Cheng Du Shi, CN HQ	Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more	Locations Durham, US HQ Buenos Aires, AR Melbourne, AU Sydney, AU Zaventem, BE Sao Paulo, BR Sofia, BG see more	Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more
Employees	Employees N/A	Employees 81,0008% decrease	Employees 19,000	Employees 75,883
Valuation ($)	Valuation ($) N/A	Valuation ($) 163.9 b	Valuation ($) 1.6 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $62.6b (FY, 2025)	Revenue (est.) $2.7b (FY, 2025)	Revenue (est.) $56.7b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods $16.1b (FY, 2025)	Cost of goods N/A	Cost of goods $8.4b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit $46.5b (FY, 2025)	Gross profit N/A	Gross profit $49.8b (FY, 2025)
Net income	Net income N/A	Net income $7.8b (FY, 2025)	Net income ($986.2m) (FY, 2025)	Net income $14b (FY, 2025)
Operating ⚠
Countries	Countries N/A	Countries 200 (FY, 2024)	Countries 90 (Jul, 2023)	Countries N/A
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products 32 (FY, 2024)	Phase III Trials Products N/A	Phase III Trials Products 44 (FY, 2022)
Registration Phase Products	Registration Phase Products N/A	Registration Phase Products 5 (FY, 2024)	Registration Phase Products N/A	Registration Phase Products 8 (FY, 2022)